Literature DB >> 23141211

Prevalence and spread of multidrug resistant Escherichia coli isolates among nursing home residents in the southern part of The Netherlands.

C F M van der Donk1, J M G A Schols, C J Driessen, R G P Hagenouw, A Meulendijks, E E Stobberingh.   

Abstract

OBJECTIVES: Empiric antibiotic treatment should be based on recent surveillance data. Therefore, we conducted a surveillance of (multidrug) resistance of Escherichia coli and antibiotic use among Dutch nursing home (NH) residents. Pulsed-field gel electrophoresis and multilocus sequence typing were used to describe the spread of multidrug-resistant strains.
DESIGN: Observational study.
SETTING: Five NHs in the southern part of The Netherlands. PARTICIPANTS: A total of 337 NH residents from both somatic and psychogeriatric wards. MEASUREMENTS: The prevalence and spread of antibiotic resistance and multidrug resistant E. coli isolates collected from urine samples and antibiotic use among the NH residents were investigated.
RESULTS: A total of 208 E. coli isolates were collected from 308 urine samples. Resistance to amoxicillin-clavulanic acid was 23% and resistance to ciprofloxacin was 16%. Resistance to trimethoprim-sulfamethoxazole was 19%, whereas nitrofurantoin resistance was less than 1%. Multidrug resistance was observed in 28 of the 208 isolates (13%). Several isolates showed a similar pulsed-field gel electrophoresis pulsotype and multilocus sequence typing type. Sequence type (ST) 131 was the most prevalent (48%) and was demonstrated in all NHs and with four different pulsotypes. Consumption of antibiotics for systemic use was 64.4 defined daily dose (DDD)/1000 residents/day. Amoxicillin-clavulanic acid was most frequently prescribed (20.92 DDD/1000 residents/day), followed by the quinolones (14.8 DDD/1000 residents/day).
CONCLUSION: We observed a high prevalence of antibiotic resistance and antibiotic use. In particular, the use of and resistance to fluoroquinolones is concerning. Because of the high prevalence of resistance, many agents are no longer suitable for empiric treatment. E. coli ST131, which has also been demonstrated in this study, poses a potential risk to this vulnerable population. We have clearly demonstrated that the resistance among NH residents is different from elderly living at home and hospitalized patients, and with the emergence of resistant strains, such as ST131, NHs are a potential reservoir for multidrug resistant bacteria.
Copyright © 2013. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23141211     DOI: 10.1016/j.jamda.2012.09.026

Source DB:  PubMed          Journal:  J Am Med Dir Assoc        ISSN: 1525-8610            Impact factor:   4.669


  10 in total

1.  Global Extraintestinal Pathogenic Escherichia coli (ExPEC) Lineages.

Authors:  Amee R Manges; Hyun Min Geum; Alice Guo; Thaddeus J Edens; Chad D Fibke; Johann D D Pitout
Journal:  Clin Microbiol Rev       Date:  2019-06-12       Impact factor: 26.132

Review 2.  A new clone sweeps clean: the enigmatic emergence of Escherichia coli sequence type 131.

Authors:  Ritu Banerjee; James R Johnson
Journal:  Antimicrob Agents Chemother       Date:  2014-05-27       Impact factor: 5.191

3.  Long-Term Carriage of Ciprofloxacin-Resistant Escherichia coli Isolates in High-Risk Nursing Home Residents.

Authors:  Miriam D Ismail; Ting Luo; Sara McNamara; Bonnie Lansing; Evonne Koo; Lona Mody; Betsy Foxman
Journal:  Infect Control Hosp Epidemiol       Date:  2016-01-19       Impact factor: 3.254

4.  Is living in a border region a risk for a high prevalence of resistance?

Authors:  C F M van der Donk; M I A Rijnders; G A Donker; A J de Neeling; S Nys; E E Stobberingh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-02-10       Impact factor: 3.267

5.  Long-Term Care Facilities Are Reservoirs for Antimicrobial-Resistant Sequence Type 131 Escherichia coli.

Authors:  Mary J Burgess; James R Johnson; Stephen B Porter; Brian Johnston; Connie Clabots; Brian D Lahr; James R Uhl; Ritu Banerjee
Journal:  Open Forum Infect Dis       Date:  2015-02-17       Impact factor: 3.835

Review 6.  Epidemic potential of Escherichia coli ST131 and Klebsiella pneumoniae ST258: a systematic review and meta-analysis.

Authors:  M J D Dautzenberg; M R Haverkate; M J M Bonten; M C J Bootsma
Journal:  BMJ Open       Date:  2016-03-17       Impact factor: 2.692

7.  Prolonged colonisation with Escherichia coli O25:ST131 versus other extended-spectrum beta-lactamase-producing E. coli in a long-term care facility with high endemic level of rectal colonisation, the Netherlands, 2013 to 2014.

Authors:  Ilse Overdevest; Manon Haverkate; Jacobien Veenemans; Yvonne Hendriks; Carlo Verhulst; Ans Mulders; Willemijn Couprie; Martin Bootsma; James Johnson; Jan Kluytmans
Journal:  Euro Surveill       Date:  2016-10-20

8.  Microbiota-associated risk factors for asymptomatic gut colonisation with multi-drug-resistant organisms in a Dutch nursing home.

Authors:  Quinten R Ducarmon; Elisabeth M Terveer; Romy D Zwittink; Ed J Kuijper; Sam Nooij; Michelle N Bloem; Karuna E W Vendrik; Monique A A Caljouw; Ingrid M J G Sanders; Sofie M van Dorp; Man C Wong
Journal:  Genome Med       Date:  2021-04-07       Impact factor: 11.117

9.  Resident-Related Factors Influencing Antibiotic Treatment Decisions for Urinary Tract Infections in Dutch Nursing Homes.

Authors:  Lisa Marie Kolodziej; Sacha Daniëlle Kuil; Menno Douwe de Jong; Caroline Schneeberger
Journal:  Antibiotics (Basel)       Date:  2022-01-21

10.  SslE elicits functional antibodies that impair in vitro mucinase activity and in vivo colonization by both intestinal and extraintestinal Escherichia coli strains.

Authors:  Barbara Nesta; Maria Valeri; Angela Spagnuolo; Roberto Rosini; Marirosa Mora; Paolo Donato; Christopher J Alteri; Mariangela Del Vecchio; Scilla Buccato; Alfredo Pezzicoli; Isabella Bertoldi; Lapo Buzzigoli; Giovanna Tuscano; Maria Falduto; Valentina Rippa; Yaqoub Ashhab; Giuliano Bensi; Maria Rita Fontana; Kate L Seib; Harry L T Mobley; Mariagrazia Pizza; Marco Soriani; Laura Serino
Journal:  PLoS Pathog       Date:  2014-05-08       Impact factor: 6.823

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.